Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
quarterly or semiannual financial statement / - Increase in turnover by 5.7% to EUR 170.6 m after three quarters - Profit per share climbs from EUR 0.26 to EUR 0.86 - Renovation of the rehab area completed

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.

9-month report


Ad hoc release according to § 15 WpHG Berlin 8th May 2008. Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) was able to further increase its operating turnover by 5.7% to EUR 170.6 m in the first three quarters of the financial year 2007/2008 (previous year EUR 161.4 m). The EBIT improved from EUR 10.2 m to EUR 12.6 m. The EBITDAR expanded from EUR 44.7 m to EUR 51.0 m. The unadjusted annual surplus increased from EUR 3.1 m to currently EUR 10.4 m. For the profit per share this corresponds to EUR 0.86, following EUR 0.26 in the comparison period of the previous year. The balanced equity is EUR 82.2 m (previous year: EUR 66.3 m). Thus the equity ratio could be expanded once more and is now at 32.6%. Due to the latest sale- and-lease-back transaction, the net debt of EUR 111.6 m in the previous year was reduced to currently EUR 69.8 m.

The return according to DVFA/SG, adjusted by the starting costs of care costs and costs of idleness of rehabilitation facilities, decreased from EUR 9.2 m to currently EUR 7.4 m. Although Rehabilitation was able to significantly increase its return from EUR -1.1 m to EUR 0.8 m, the return in Care dropped from EUR 10.3 m to EUR 6.6 m. Therefore, the profit per share according to DVFA/SG achieved EUR 0.60, following EUR 0.75 in the comparison period of the previous year. The adjusted EBITDAR was at EUR 45.9 m at the end of the reporting period, following EUR 49.9 m in the previous year. The adjusted EBIT reduced from EUR 16.7 m to currently EUR 12.5 m. The occupancy rate in the consolidated group was increased from 89.9% to 92.5%.

The core segment Care, in which Marseille-Kliniken represents 86% of the group's bed capacity, was able to continue gaining in turnover. With EUR 132.7 m Marseille-Kliniken achieved an increase in turnover of EUR 8.9 m during the reporting period in this segment, as opposed to EUR 123.8 m turnover in the period of the previous year. The occupancy rate was further improved with the development of 92.8% in the previous year to currently 93.4%. The return according to DVFA/SG reduced from EUR 10.3 m to currently EUR 6.6 m. This is essentially accounted for by high, unadjusted one-time investments in a leading quality management system in Germany that incurred corresponding expenses, and the related roll-out costs for the broad introduction of eLearning. In addition, increased energy costs, higher advertising expenditures and advanced maintenance costs were a burden.

The positive development continued in Rehabilitation in the 3rd quarter. The segment has completed the turnaround and is no longer burdening the consolidated operating profits this financial year anymore. This way the occupancy rate in the segment was able to be increased significantly from 76.8% in the previous year to 89.2%, with 1,283 beds. With EUR 37.9 m, turnover in Rehabilitation was with the reduced capacity EUR 0.3 m over the previous year's value of EUR 37.6 m in the reporting period. In the result according to DVFA/SG, with EUR 0.8 m once again a positive contribution was able to be booked, after the value of the previous year's EUR -1.1 m. Based on the division's successful renovation, the company maintains its intent to sell off Rehabilitation by selling the operating businesses as soon as the uncertainty on the financial markets has calmed down.

The number of beds was increased to a total of 8,899 beds (+134) in the current financial year. There are a further 4 locations with 600 beds currently under construction, and further bed capacities will be created in the Care segment in the development of assisted living. In relation to this locations have already been secured in seven eastern German cities for the purchase of operating companies for an additional 3000 flats for assisted living, which will be gradually taken over into the company in the coming financial years.

The company has corrected its forecast turnover by EUR 7.0 m to EUR 233.0 m for the entire financial year 2007/2008. The main reason for this is the delayed occupancy of expansion facilities in Care. In contrast, the EBIT forecast of EUR 24.0 and the results after tax of EUR 18.0 m remain unchanged. The profit per share will therefore increase to EUR/share 1.48 in comparison to EUR/share 0.75 in the previous year.

End of the ad-hoc release

end of announcement                               euro adhoc

Further inquiry note:

If you have any questions, please contact:

Marseille-Kliniken AG
Axel Hölzer
Alte Jakobstraße 79/80
10709 Berlin
Tel.: +49 (0) 30 / 246 32-400
Fax: +49 (0) 30 / 246 32-401

Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Tel.: +49 (0) 40 / 320 279 10
Fax: +49 (0) 40 / 320 279 114

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hamburg / regulated dealing

Original-Content von: Marseille-Kliniken AG, übermittelt durch news aktuell

Weitere Meldungen: Marseille-Kliniken AG

Das könnte Sie auch interessieren: